Literature DB >> 17414580

Management of hypertensive crises.

Carlos Feldstein1.   

Abstract

Hypertensive emergencies are life-threatening conditions because their course is complicated with acute target organ damage. They can present with neurological, renal, cardiovascular, microangiopathic hemolytic anemia, and obstetric complications. After diagnosis, they require the immediate reduction of blood pressure (in <1 hour) with intravenous drugs such as sodium nitroprusside, administered in an intensive care unit. These patients present with a mean arterial pressure >140 mm Hg and grade III to IV retinopathy. Only occasionally do they have hypertensive encephalopathy, reflecting cerebral hyperperfusion, loss of autoregulation, and disruption of the blood-brain barrier. In hypertensive emergencies, blood pressure should be reduced about 10% during the first hour and another 15% gradually over the next 2 to 3 hours to prevent cerebral hypoperfusion. The exception to this management strategy is aortic dissection, for which the target is systolic blood pressure <120 mm Hg after 20 minutes. Oral antihypertensive therapy can usually be instituted after 6 to 12 hours of parenteral therapy. Hypertensive urgencies are severe elevations of blood pressure without evidence of acute and progressive dysfunction of target organs. They demand adequate control of blood pressure within 24 hours to several days with use of orally administered agents. The purpose of this review is to provide a rational approach to hypertensive crisis management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414580     DOI: 10.1097/01.pap.0000249908.55361.de

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  9 in total

Review 1.  Drug treatment of hypertensive crisis in children.

Authors:  Christopher A Thomas
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

2.  Pharmacokinetics and tissue distribution of clevidipine and its metabolite in dogs and rats.

Authors:  Ying Zhou; Xiao-Meng He; Hu-Qun Li; Yang Ni; Ming-Zhen Xu; Hui Chen; Wei-Yong Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 3.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575

4.  Attitudes and practices of resident physicians regarding hypertension in the inpatient setting.

Authors:  Robert Neal Axon; Robin Garrell; Kyle Pfahl; Julie E Fisher; Yumin Zhao; Brent Egan; Alan Weder
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-09       Impact factor: 3.738

5.  Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.

Authors:  William B Smith; Thomas C Marbury; Steven F Komjathy; Mark S Sumeray; Gregory C Williams; Ming-yi Hu; Diane R Mould
Journal:  Eur J Clin Pharmacol       Date:  2012-03-29       Impact factor: 2.953

Review 6.  Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review.

Authors:  Ahmed S Awad; Michael E Goldberg
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

7.  Emergency Room Treatment of Hypertensive Crises.

Authors:  Sabina Salkic; Selmira Brkic; Olivera Batic-Mujanovic; Farid Ljuca; Almedina Karabasic; Sehveta Mustafic
Journal:  Med Arch       Date:  2015-10-04

8.  Clinical presentation of hypertensive crises in emergency medical services.

Authors:  Sabina Salkic; Olivera Batic-Mujanovic; Farid Ljuca; Selmira Brkic
Journal:  Mater Sociomed       Date:  2014-02-20

9.  Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial.

Authors:  Chad M Cannon; Phillip Levy; Brigitte M Baumann; Pierre Borczuk; Abhinav Chandra; David M Cline; Deborah B Diercks; Brian Hiestand; Amy Hsu; Preeti Jois; Brian Kaminski; Richard M Nowak; Jon W Schrock; Joseph Varon; W Frank Peacock
Journal:  BMJ Open       Date:  2013-03-26       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.